Introduction
The Human CD268/BAFFR HEK293T Stable Cell Line is a valuable tool for studying the structure, activity, and potential therapeutic applications of the human CD268 receptor, also known as the B-cell activating factor receptor (BAFFR). This stable cell line is derived from human embryonic kidney cells (HEK293T) and stably expresses the human CD268 receptor, allowing for the study of its function and potential as a therapeutic target.
Structure of CD268/BAFFR
The human CD268 receptor is a member of the tumor necrosis factor receptor superfamily and is primarily expressed on B cells. It is a type III transmembrane protein, with a large extracellular domain containing a cysteine-rich domain and a tumor necrosis factor receptor homology domain. The intracellular domain of CD268 contains a death domain, which is important for signaling and interaction with other proteins.
Activity of CD268/BAFFR
The primary function of CD268 is to bind to the B-cell activating factor (BAFF), a cytokine that plays a crucial role in B cell development and survival. Upon binding to BAFF, CD268 activates signaling pathways that promote B cell survival, proliferation, and differentiation. This activity is essential for the maintenance of a healthy immune system and is dysregulated in various autoimmune diseases and B cell malignancies.
Application in Flow Cytometry
The Human CD268/BAFFR HEK293T Stable Cell Line is a valuable tool for flow cytometry studies. The stable expression of CD268 allows for the specific detection and analysis of BAFFR-expressing cells, such as B cells, in a mixed population. This is particularly useful in studying changes in BAFFR expression under different conditions or in disease states. Additionally, this stable cell line can be used as a positive control in flow cytometry experiments to validate the specificity and sensitivity of anti-BAFFR antibodies.
Potential Therapeutic Target
Due to its crucial role in B cell survival and proliferation, CD268 has been identified as a potential therapeutic target for various diseases. In autoimmune diseases such as systemic lupus erythematosus and rheumatoid arthritis, dysregulated BAFF signaling and increased CD268 expression have been observed, making CD268 a promising target for therapy. In B cell malignancies, targeting CD268 with specific antibodies or inhibitors may provide a novel approach for treatment.
Conclusion
In summary, the Human CD268/BAFFR HEK293T Stable Cell Line is a valuable tool for studying the structure, activity, and potential therapeutic applications of the human CD268 receptor. Its stable expression of CD268 allows for specific detection and analysis of BAFFR-expressing cells, making it a useful tool for flow cytometry studies. Additionally, CD268 has been identified as a potential therapeutic target for various diseases, making this stable cell line a valuable resource for drug discovery and development.
There are no reviews yet.